20 May 2013
Keywords: fda, clears, mannkind, mkc1106-pp, immunotherapy, ind, drug
Article | 04 December 2006
US drug discovery firm MannKind Corp says that an Investigational New Drug application for its range of MKC1106-PP-based immunotherapy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 December 2006
27 November 2006
17 May 2013
© 2013 thepharmaletter.com